23andMe turned an FDA shutdown into approved consumer genetic testing

In 2013, the FDA shut down 23andMe's DNA test kits, warning that false assessments could create health consequences. The consumer-genetics company had a compelling product but could not sell health interpretations without regulatory clearance.

The turning-point decision was to work through the FDA rather than treat the checkpoint as a dead end. After four years of maneuvering, 23andMe secured approval in April 2017 for tests covering 10 diseases, including Parkinson's disease and Alzheimer's disease. It also widened the change: its drug-research arm would use its database to pursue therapeutics, while the company said it would address the lack of genetic diversity in its customer base.

The strategy produced a broader platform than a test kit alone. 23andMe had attracted more than 2 million customers worldwide and then raised a $250 million Series F led by Sequoia in September 2017, giving it capital to continue the consumer-health and research push.

After four years of regulatory maneuvering, 23andMe secured FDA approval for 10 disease tests, had more than 2 million customers, and raised a $250 million Series F.

The FDA shutdown made the original health-testing proposition commercially and legally untenable.

A narrow approval restored a legal path to market instead of forcing the company to abandon health information.

The customer database could support drug discovery, giving the company a second route beyond selling test kits.

Addressing genetic diversity was necessary for the product to serve more than its largely European customer base.

When regulation blocks a disruptive product, turn the checkpoint into the roadmap: win a narrow approval, learn from the constraint, and expand from a defensible base.

23andMe continued working with the FDA on additional disease classes and positioned its research arm to improve drug discovery. The company reframed the crisis as a move toward a consumer-health and therapeutics model, with the original regulatory blockage converted into an approved product and a larger research agenda.